Northwest Biotherapeutics
NWBO
NWBO was delisted on the 16th of December, 2016.
58 hedge funds and large institutions have $52.5M invested in Northwest Biotherapeutics in 2014 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 19 increasing their positions, 12 reducing their positions, and 3 closing their positions.
467% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 3
209% more capital inflows, than outflows
Capital inflows: $11M | Capital outflows: $3.55M
58% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 12
51% more call options, than puts
Call options by funds: $4.19M | Put options by funds: $2.78M
32% more funds holding
Funds holding: 44 → 58 (+14)
13.49% more ownership
Funds ownership: 0% → 13.49% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$2.03M |
| 2 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$1.19M |
| 3 |
Morgan Stanley
New York
|
+$1.07M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$835K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$796K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Whitebox Advisors
Minneapolis,
Minnesota
|
-$2.07M |
| 2 |
Credit Suisse
Zurich,
Switzerland
|
-$903K |
| 3 |
BlackRock Advisors
Wilmington,
Delaware
|
-$212K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$107K |
| 5 |
Woodstock Corp
Boston,
Massachusetts
|
-$79.8K |
NWBO Hedge Fund Activity: Q1 2014 in Review
58 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics (NWBO) for Q1 2014, worth a combined $52.5M — up 124% from $23.5M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new NWBO positions and 3 closed out — a net gain of 14 holders — while 19 added to existing stakes and 12 trimmed.
The largest buyer was Franklin Resources, adding an estimated $2.03M. The largest seller was Whitebox Advisors, exiting entirely with an estimated $2.07M sold.
- 58 institutional investors held Northwest Biotherapeutics (NWBO) as of Q1 2014, up from 44 in Q4 2013.
- Funds reported $52.5M of Northwest Biotherapeutics stock for Q1 2014, up 124% quarter-over-quarter.
- 17 funds opened new Northwest Biotherapeutics positions in Q1 2014 and 3 closed out, a net change of +14 holders.
- The largest Northwest Biotherapeutics buyer in Q1 2014 was Franklin Resources, an estimated $2.03M added.
- The largest Northwest Biotherapeutics seller in Q1 2014 was Whitebox Advisors, an estimated $2.07M sold.
Based on aggregated 13F filings for Q1 2014.